According to Organic Market Research report, “Saudi Arabia Influenza Vaccine Market – Industry Share, Size, Trends, Competition Forecast & Opportunities, 2028”, the Saudi Arabia Market stood at USD 76.15 million in 2022, which is estimated to reach USD 140.22 million in 2030, with a CAGR of 7.93% for the forecast period of 2023-2030. Largely driven by increased public health awareness and strong government assistance, the influenza vaccine market in Saudi Arabia has undergone substantial growth and transformation in recent years. The requirement for vaccines has risen owing to more frequent influenza outbreaks, intending to decrease the social and economic impacts of seasonal flu.

The global influenza vaccine market is witnessing significant growth due to different factors, including the increased focus of governments on offering better public healthcare, innovations in vaccine research, and decreased risks of side effects linked with influenza vaccines. The rapid expansion of the market is also propelled by the development of innovative vaccines, an increase in medical tourism, and increased investment in R&D activities. Additionally, the market is witnessed to benefit from the availability of different WHO-prequalified influenza vaccines and the expansion of regular immunization programs.

Furthermore, the growing frequency of influenza cases and the noteworthy impact of seasonal outbreaks have led to a higher requirement for influenza vaccines. Like other countries, Saudi Arabia has witnessed notable influenza activity during flu seasons, which has strengthened efforts to encourage immunization to decrease virus transmission and its public health impact. The Saudi Arabian influenza vaccine market has also promoted innovations in vaccine technologies and a broader variety of vaccine options. Notably, the introduction of quadrivalent vaccines, which safeguard against four several influenza strains, has attained considerable popularity in recent years owing to their enhanced efficacy.

Download Free Sample Report

Saudi Arabia has been making substantial efforts to improve its pharmaceutical infrastructure, particularly in terms of growing the accessibility and administration of influenza vaccines. Identifying the significance of proactive healthcare measures including influenza vaccination in reducing the effects of seasonal flu and preventing public health, the nation has enthusiastic resources for progressing pharmaceutical education and research institutions. This commitment focuses on developing a skilled workforce and propelling scientific progress. Universities and research centers in Saudi Arabia have established partnerships with international organizations to enhance pharmaceutical education programs, conduct research, and motivate innovation.

For instance, in June 2023, Saudi Arabia's Public Investment Fund (PIF) launched Lifera, a new Contract Development and Manufacturing Organization (CDMO). Lifera focuses on propelling the growth of the domestic biopharmaceutical sector, to improve national resilience and position Saudi Arabia as a leading global pharmaceutical manufacturing hub. Lifera will primarily aim to introduce a variety of pharmaceutical products, comprising insulins, vaccines, plasma therapeutics, monoclonal antibodies, cell and gene therapies, and ground-breaking small molecules. The introduction of Lifera underscores Saudi Arabia's commitment to developing local pharmaceutical manufacturing capabilities and improving the biopharmaceutical industry.

According to influenza surveillance reports from the World Health Organization (WHO), there has been a prominent rise in different influenza-related indicators. The percentage of positive influenza cases has increased efficiently, from 3.75% to 25.11%. Similarly, the number of influenza-like illnesses (ILIs) has increased from 45 to 344, and the number of severe acute respiratory infections (SARIs) has touched from 82 to 303 when comparing the corresponding periods of 2021 and 2022. Due to a significant increase in influenza and influenza-like illnesses (ILIs), the Ministry of Health (MOH) in Saudi Arabia has presently increased the population to visit primary healthcare centers (PHCs) for the seasonal influenza vaccine (SIV). The MOH has witnessed an efficient increase in the number of influenza cases and ILIs throughout the 2022 flu season compared to previous years, signifying a potential strain on the Kingdom's healthcare system. This increased incidence of ILIs and severe acute respiratory infections (SARIs) during 2022 has supported to the growth of the influenza vaccine market in Saudi Arabia.

In 2021, Saudi Arabia's Ministry of Health (MOH) launched an awareness campaign to encourage flu vaccinations, targeting population groups most susceptible to seasonal influenza. The campaign focuses on motivating citizens and residents, particularly those at higher perils of flu-related complications—such as the elderly, individuals with chronic diseases, immunocompromised people, pregnant women, healthcare personnel, and the general community—to receive the flu shot. In 2022, Saudi Arabia announced its most advanced surveillance system to date, the Integrated Influenza Sentinel Surveillance System (IISS). This advancement followed the positive implementation of the National Influenza Surveillance Development Plan throughout the COVID-19 pandemic. The IISS includes a network of 100 sites, including 30 hospitals and 70 primary healthcare clinics. This all-inclusive system corporates on-site molecular testing for influenza and respiratory syncytial viruses, quick COVID-19 testing, and dedicated training for healthcare providers. All test data are sent to the Public Health Laboratory at the Public Health Authority for subtyping, genetic sequencing, and data allocation. A foremost component of the IISS is the COVID-19 National Genomic Surveillance Program, which is important for intensive care SARS-CoV-2 transmission patterns and noticing emerging alternatives early.

Based on the formulation, quadrivalent dominates the market growth. The rising demand for quadrivalent flu vaccines is positively impacting the Saudi Arabia influenza vaccine market. Quadrivalent vaccines focus on proposing protection against two influenza A viruses and two influenza B viruses, thereby covering a wider range of flu viruses compared to the previously utilized trivalent vaccines. Traditionally, flu vaccines targeted three dissimilar flu viruses: influenza A(H1N1), influenza A(H3N2), and one influenza B virus. However, with the presence of the second lineage of the B virus, quadrivalent vaccines offer improved defense against circulating flu viruses. This extended coverage renders quadrivalent vaccines actual in safeguarding against a broader spectrum of flu viruses.

Contact Us:
Mob : +91 9319642100
Noida One Tower Sec 62 Noida 201301
Sales  : sales@organicmarketresearch.com
Website : https://www.organicmarketresearch.com